目的 探讨都梁软胶囊联合佐米曲普坦治疗偏头痛的临床疗效。方法 选取2015年8月-2016年8月在开封市第二人民医院接受治疗的偏头痛患者94例，根据患者意愿分为对照组（47例）和治疗组（47例）。对照组口服佐米曲普坦片，2.5 mg/次，1次/d。治疗组在对照组的基础上口服都梁软胶囊，3粒/次，3次/d。两组患者连续治疗4周。评价两组患者临床效果，同时比较两组患者治疗前后临床症状评分和VAS评分变化。结果 治疗后，对照组和治疗组的总有效率分别为80.85%和95.74%，两组总有效率比较差异具有统计学意义（P<0.05）。治疗后，两组患者头痛发作次数、头痛持续时间及伴随症状评分均显著下降，同组治疗前后差异具有统计学意义（P<0.05）；且治疗后治疗组上述临床症状改善更显著，两组比较差异有统计学意义（P<0.05）。治疗后，两组VAS评分均降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗组患者VAS评分降低更显著，两组比较差异有统计学意义（P<0.05）。结论 都梁软胶囊联合佐米曲普坦治疗偏头痛效果显著，利于临床症状的改善，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Duliang Soft Capsules combined with zolmitriptan in treatment of migraine. Methods Patients (94 cases) with migraine in Kaifeng Second People's Hospital from August 2015 to August 2016 were divided into control group (47 cases) and treatment group (47 cases) based on patients' willingness. Patients in the control group were po administered with Zolmitriptan Tablets, 2.5 mg/time, once daily. Patients in the treatment group were po administered with Duliang Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 week. After treatment, the clinical efficacy was evaluated, clinical symptom score and VAS score in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.85% and 95.74%, respectively, and there was difference between two groups (P<0.05). After treatment, the headache attack frequency, headache duration, and accompanying symptom score in two groups was significantly decreased, the difference was statistically significant in the same group (P<0.05). And the improvement of these symptoms in the treatment group was significantly better than that in the control group, with significant difference between two groups (P<0.05). After treatment, VAS score in treatment group was significantly decreased, the difference was statistically significant in the same group (P<0.05). And the VAS score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05).Conclusion Duliang Soft Capsules combined with zolmitriptan has a significant clinical effect in treatment of migraine, can improve the clinical symptoms, which has a certain clinical application value.